Fig. 1.

STAMBP expression is upregulated in NSCLC tissues. (A) The STAMBP protein expression in paired tumor tissues (T) and adjacent noncancerous tissues (N) from NSCLC patients was examined by Western blotting. β-Actin was used as the internal control. (B) The relative mRNA expression of STAMBP was analyzed in 10 paired tumor and noncancerous tissues from LUAD patients from the GEO database. The ratio of STAMBP expression in the tumor tissues to the controls for each patient is shown as a log2-transformed fold change. (C) Box (25−75th percentiles) and whisker (minimum-maximum) plots of STAMBP expression in the normal lung and tumor tissues from LUAD patients; the horizontal line inside the box indicates the median (the 50th percentile). P values were calculated by the Kruskal-Wallis test. (D) Typical IHC staining of STAMBP in tumor and noncancerous tissues. IHC staining was performed in 75 pairs of tissues, and representative images from 3 pairs (A03 and A04; D15 and D16; J03 and J04) are shown. Scale bar represents 100 µm (200 ×) and 50 µm (400 ×). The IHC scores were assessed, and the chi-squared test was used to compare the differences. (E) Kaplan-Meier survival analyses were conducted to evaluate the prognostic significance of STAMBP for OS and DFS in LUAD patients. NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; OS, overall survival; DFS, disease-free survival.